CNIPA.AI
검색으로 돌아가기
기록

Cancer Cytotoxic Exosome Formulations and Methods for Use in Treating Cancer

발명심사 중
2조회수
20청구항 · 1 독립항
§ Ⅰ

개요

발명자

Joaquin J. Jimenez; John P. McCook

IPC 분류

A61K 35/15A61K 9/A61K 40/17A61P 35/2C12N 5/786C12N 5/787

CPC 분류

A61K35/15A61K9/19A61K40/17A61P35/2C12N5/642C12N5/645A61K2239/38

Compositions and methods for treating cancer, particularly leukemia, using a cytotoxic composition comprising monocytes activated by-glucan. The monocytes are preferably incubated with the β-glucan and then processed to extract particles, such as microvesicles and exosomes from the treated monocytes to produce the cytotoxic composition. Preferably the cytotoxic composition comprises at least 50% exosomes having a size of 150 nm or less that are activated with β-glucan. Zymosan is the preferred β-glucan. The cytotoxic composition has an apoptosis effect. When a subject having cancer is treated according to preferred embodiments, the cytotoxic composition preferably induces a cytokine response in the subject's immune system. The combination of the cytotoxic composition and cytokine response are synergistic.

원문 (중국어)

Compositions and methods for treating cancer, particularly leukemia, using a cytotoxic composition comprising monocytes activated by-glucan. The monocytes are preferably incubated with the β-glucan and then processed to extract particles, such as microvesicles and exosomes from the treated monocytes to produce the cytotoxic composition. Preferably the cytotoxic composition comprises at least 50% exosomes having a size of 150 nm or less that are activated with β-glucan. Zymosan is the preferred β-glucan. The cytotoxic composition has an apoptosis effect. When a subject having cancer is treated according to preferred embodiments, the cytotoxic composition preferably induces a cytokine response in the subject's immune system. The combination of the cytotoxic composition and cytokine response are synergistic.